Immunotherapy in breast cancer: An introduction

Breast

Volumn 37, Issue , 2018, Pages 196-199

  Disis, Mary L ^a   Stanton, Sasha E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antigen; Immune checkpoint inhibitor; Immunotherapy; Tumor infiltrating lymphocytes; Type I T cells; Vaccine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; PERTUZUMAB; PLACEBO; PROTEIN MUC 1; PROTEIN P53; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STROMA CELL; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CELLULAR IMMUNITY; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; TUMOR MICROENVIRONMENT;

EID: 85011308330     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2017.01.013     Document Type: Article

References (29)

1. Disis, M.L., Immune regulation of cancer. J Clin Oncol 28:29 (2010), 4531–4538.
2. Magarian-Blander, J., et al. Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells. Glycoconj J 13:5 (1996), 749–756.
3. Brossart, P., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:12 (1999), 4309–4317.
4. Fremd, C., et al. Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. Oncoimmunology 5:1 (2016), 1–7.
5. Goodell, V., et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:3 (2008), 449–454.
6. Tabuchi, Y., et al. Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Res Treat 157:1 (2016), 55–63.
7. Montgomery, R.B., et al. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:2 (2005), 650–656.
8. Disis, M.L., et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:3 (2000), 245–252.
9. Inokuma, M., et al. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol 179:4 (2007), 2627–2633.
10. Katayama, H., et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis. Cancer Res 75:16 (2015), 3246–3254.
11. Ladd, J.J., et al. Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res 73:5 (2013), 1502–1513.
12. Fracol, M., et al. Loss of anti-HER-3 CD4+ T-helper type 1 immunity occurs in breast tumorigenesis and is negatively associated with outcomes. Ann Surg Oncol 24:2 (2017), 407–417.
13. Kaewkangsadan, V., et al., Crucial Contributions by T Lymphocytes (effector, regulatory, and checkpoint inhibitor) and cytokines (TH1, TH2, and TH17) to a pathological complete response induced by neoadjuvant chemotherapy in women with breast cancer, J Immunol Res, p. 4757405.
14. Shiao, S.L., et al. TH2-Polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res 3:5 (2015), 518–525.
15. Denkert, C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1 (2010), 105–113.
16. Adams, S., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:27 (2014), 2959–2966.
17. Luen, S.J., et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18:1 (2017), 52–62.
18. Stanton, S.E., Adams, S., Disis, M.L., Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2 (2016), 1354–1360.
19. Ladoire, S., et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 105:3 (2011), 366–371.
20. Shi, Y., et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages. J Immunol 194:9 (2015), 4379–4386.
21. Di Modica, M., et al. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget 7:1 (2016), 255–265.
22. Petricevic, B., et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 11 (2013), 307–317.
23. Datta, J., et al. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res 17 (2015), 71–85.
24. Beckers, R.K., et al. PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Pathology 48:Suppl 1 (2016), S146–S147.
25. Nanda, R., et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34:21 (2016), 2460–2467.
26. Stanton, S.E., et al. Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. J Immunother Cancer 4 (2016), 27–31.
27. Czerniecki, B.J., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67:4 (2007), 1842–1852.
28. Shiao, S.L., Coussens, L.M., The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15:4 (2010), 411–421.
29. Zitvogel, L., et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39:1 (2013), 74–88.